Bridging Deep Biology with AI
About ProtLLM Inc.
Designing the Future of Antibody Discovery
PROTLLM Inc. is a biotech startup in formation, architecting a platform that fuses molecular biology, antibody engineering, and artificial intelligence. Our goal is to build a closed-loop, IP-cleared engine for therapeutic antibody design—starting with intrinsically disordered neoantigens in cancer.
We’re currently developing workflows that integrate AI models like AlphaFold3 and BoltzGen with PCR-based assay design, structural prediction, and translational strategy. Every step is guided by scientific rigor, legal defensibility, and a commitment to innovation.
What We’re Building
A modular antibody design platform with built-in IP and attribution safeguards
AI-enhanced pipelines for targeting disordered cancer neoantigens
A collaborative team structure spanning science, AI, IP/legal, and strategy
Why It Matters
Disordered neoantigens represent one of the most elusive frontiers in cancer biology. PROTLLM aims to make them druggable—safely, swiftly, and strategically.
FAQ
What is Protllm?
ProtLLM Inc. is a biotech company in formation, focused on integrating advanced AI tools into therapeutic discovery. By combining molecular biology, protein structure modeling, and neural network intelligence, ProtLLM aims to transform how therapies are designed, validated, and translated.
What do you specialize in?
We specialize in AI and antibody research innovations.
How can I contact you?
You can contact us via our website's contact form.
Where are you located?
We are located in Malvern, Pennsylvania
Do you offer internships?
We will be able to offer internship in near future. Please email us.
What is your mission statement?
Our mission is to innovate through AI in biotechnology.